These five come up together in nootropic-peptide discussion, but they are not rivals. They target different things, and the community talks about them additively - more "you might also try" than "either-or." Adamax joins the group as the newest entry in this lineage: a structural descendant of Semax with more ambitious pharmacokinetic design and zero published research of its own. That gap is the most useful thing this comparison can show.
The original four address different targets, which is why framing them as a contest misses the point. Semax is used for cognition and neuroprotection, Selank for anxiety and calm, DSIP for sleep, and Cerebrolysin as a neurotrophic agent with the deepest clinical history of the group, particularly in stroke and dementia research. Someone exploring this space is usually assembling a toolkit, not picking a single winner.
Adamax is the sharpest illustration of what this comparison can show. Its structural rationale is sound - N-terminal acetylation to slow enzymatic breakdown, a C-terminal adamantane group to improve blood-brain barrier penetration, both borrowed from established medicinal chemistry principles. The pharmacokinetic logic extends Semax's mechanism plausibly. But no published study of Adamax exists in any species. The bars are essentially empty because the evidence base is empty, not because the compound is dismissed. The score of 11 reflects that gap accurately.
On research quality, Cerebrolysin is clearly the best-studied, reaching Moderate, and it leads most of the volume-and-quality dimensions. But even it is capped below Strong by a limitation shared across this group: the literature is geographically concentrated. Cerebrolysin's strongest evidence clusters in Eastern European and Asian research, and Semax and Selank are Russian-developed with much of their published work in Russian-language journals, which limits the independent international replication the RQS rewards. Adamax inherits this same regional origin - but without even that literature base to point to.
One number stands out against the grain: DSIP scores highest on funding independence (10 out of 10), because its small and somewhat dated sleep literature is almost entirely academic. That is a genuine strength on one dimension sitting inside an otherwise thin evidence base, a reminder that a single dimension rarely tells the whole story.
So the orientation here is not a ranking to act on. It is a map: Cerebrolysin is the most-researched if evidence quality is your priority; Semax, Selank, and DSIP are earlier-stage with region-concentrated literature; and Adamax sits at the research frontier in the least productive sense - a compound with interesting engineering and no data yet. Because they target different things, the realistic question is which target you care about, not which peptide wins.